Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Guard for Steroid-Refractory Acute Graft-versus-Host Disease
NCT04128319Phase 3Terminated
- Sponsor
- Xenikos
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies, Immunotoxins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of T-Guard in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Xenikos. Primary endpoint: Complete Response at Day 28. Started Nov 2019; status: terminated.
02
Drugs
T-Guard
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04128319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128319.